Individualized Medication Guidance for Prostate Cancer CapitalBio

Features of Individualized Medication Guidance for Prostate Cancer

• Targeted therapy: Includes SNVs, InDels, CNVs, and gene rearrangements to comprehensively guide targeted drug use.

• Immunotherapy: Detects TMB and MSI indicators, as well as positive and negative immune-related genes, providing information to guide immunotherapy.

• Chemotherapy: Detects chemotherapeutic drug loci associated with prostate cancer, suggesting durg sensitivity and adverse effects.

• Hereditary risk assessment: Covers HRR pathway genes, suggesting pathogenic and suspected pathogenic variants, guides PARP inhibitor therapy, and suggests genetic risk based on family cancer history and other information.

• Prostate cancer patients with recurrence or drua resistance.

• Patients diagnosed with prostate cancer who need liquid biopsy for targeted therapy or immunotherapy.

• Newly diagnosed patients with advanced prostate cancer who need targeted therapy or immunotherapy.